Fred Ramsdell | |
---|---|
![]() Ramsdell in 2015 | |
Born | Frederick Jay Ramsdell December 4, 1960 Elmhurst, Illinois, U.S. |
Education | University of California, San Diego (BS) University of California, Los Angeles (PhD) |
Awards | Crafoord Prize (2017) Nobel Prize in Physiology or Medicine (2025) |
Scientific career | |
Institutions | Parker Institute for Cancer Immunotherapy |
Thesis | Generation of lymphokine-activated killer cells from non-natural killer cell sources: Development from human thymocytes (1988) |
Academic advisors | Sidney Golub [1] |
Frederick Jay Ramsdell [1] (born December 4, 1960) [2] is an American-French [3] immunologist. As of 2025, he works at Sonoma Biotherapeutics. [2]
In 2025, he was jointly awarded the Nobel Prize in Physiology or Medicine with Mary E. Brunkow and Shimon Sakaguchi for their work in peripheral tolerance. [4]
Ramsdell was born on December 4, 1960, in Elmhurst, Illinois. [2]
He received a Bachelor of Science degree with a major in biochemistry and cell biology from the University of California, San Diego, in 1983. [5] In the same year, he enrolled at the University of California, Los Angeles, as a doctoral student, and studied microbiology and immunology under the mentorship of Sidney Golub, receiving his Doctor of Philosophy degree in 1987. [6]
After earning his PhD, Ramsdell served a fellowship at the National Institutes of Health. After that, he joined the biopharmaceutical company Immunex, where his research focus was T cell activation and tolerance, and gene discovery. [6] [3] In 1994, he joined the Bothell, Washington-based biotechnology company Darwin Molecular (along with Mary E. Brunkow), where he established an immunology program. Darwin Molecular was acquired by Chiroscience in 1996. Three years later, Chiroscience merged with Celltech (briefly under the name Celltech Chiroscience). In 2004, Ramsdell and Brunkow left the company. [6] [7]
He joined ZymoGenetics in 2004 where he led research teams focusing on novel proteins with potential regulatory activity in lymphoid cells. [8] In 2008, he started working at Novo Nordisk where he helped establish the firm's Inflammation Research Center in Seattle and became leader of the immunobiology group. [8] [3]
Later, he served as vice president at aTyr Pharma in San Diego, [8] before joining the Parker Institute for Cancer Immunotherapy in San Francisco, where he was chief scientific officer. [6]
In 2019, he co-founded the San Francisco-based Sonoma Biotherapeutics with Jeffrey Bluestone, Qizhi Tang and Alexander Rudensky, [9] where he held the role of chief scientific officer. [10] As of 2025, he is the chair of the company's scientific advisory board. [11]
In the 1990s, while working at Celltech in Bothell, Washington, Ramsdell and Brunkow studied a strain of mice, called scurfy, characterized by serious autoimmune disease, setting out to identify the mutation responsible for the phenotype. After establishing a candidate region on the X chromosome containing approximately 20 potential genes, they identified an insertion of two base pairs in a previously unknown gene, which they named Foxp3. In 2001, in collaboration with Hans D. Ochs, Robert Wildin, and their teams, Ramsdell and Brunkow demonstrated that mutations in the human FOXP3 gene are found in IPEX syndrome, a rare autoimmune disease. [12] [13]
In 2017, Ramsdell received, jointly with Shimon Sakaguchi and Alexander Rudensky, the Crafoord Prize for research in polyarthritis. They were cited for "their discoveries relating to regulatory T cells, which counteract harmful immune reactions in arthritis and other autoimmune diseases". [14] [15]
Ramsdell was jointly awarded, with Sakaguchi and Mary E. Brunkow, the 2025 Nobel Prize in Physiology or Medicine. [4] On the day of the announcement, he was unable to be contacted to receive his prize as he was hiking off-the-grid in Idaho. [16] Ramsdell later told the BBC that his first response when he did learn the news from his wife was "I did not!", to which she replied that she had 200 text messages suggesting otherwise. [17]